Arcadian Investment Partners
152 W. 57th Street, 47th Floor, New York, NY, 10019, United States
Overview
Arcadian Investment Partners (“Arcadian”) is an investment firm focused on direct investments in growing middle-market companies. Our mission is to build industry-leading middle-market companies that generate sustainable profits for the long-term. Arcadian takes majority investment positions in portfolio companies, who then benefit from having a long-term operational and capital partner that supports management’s expansion strategy. Arcadian is backed by investors who have been long-term partners in past investments in the US, Europe, and Africa.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 1
Sector focus
- Asset Management
- Business Development
- Financial Services
Investment portfolio
- PathogenDx
Participated · Series B · Sep 2019
PathogenDx offers DNA-based testing via an advanced microarray testing platform for the cannabis, hemp, agriculture, food and beverage industries. Its technology can identify and detect up to 50 pathogens in a single test in about six hours, providing triplicate data per analyte for result certainty. The company sells DNA-testing products branded DetectX™, QuantX™ and EnviroX™ that identify, detect and quantify pathogens such as E. coli, Salmonella and Aspergillus. Led by CEO Milan Patel, PathogenDx serves a portfolio of domestic and international clients in the cannabis industry. The company raised $7.5M in a Series B to support expansion into food and agriculture testing and to build on its cannabis-market position. PathogenDx develops DNA-based pathogen testing kits and solutions for the cannabis, botanical, food, and agricultural markets. Founded in 2014 and headquartered in Tucson, Arizona, the company’s technology scales from individual plants to large agricultural fields. Its platform delivers real-time data to growers, processors, producers and ancillary service providers to detect fungi, molds, viruses and mildew. PathogenDx emphasizes simplicity, cost-effectiveness and adaptable scale for both large and small testing facilities. Management said a recent strategic investment from Salveo Capital will support growth, market expansion and continued focus on product safety. No revenue or user metrics were disclosed in the article.
Team
Kammy Moalemzadeh
Founder